Catalyst

Slingshot members are tracking this event:

Immunomedics to report updated results for sacituzumab govitecan (immu-132) in breast and lung cancers at the clinical science symposia of 2016 ASCO annual meeting

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
IMMU

100%

Additional Information

Additional Relevant Details Both abstracts are on sacituzumab govitecan, or IMMU-132, the Company’s lead antibody-drug conjugate (ADC). Sacituzumab govitecan has previously been designated by the FDA a Breakthrough Therapy for the treatment of patients with triple-negative breast cancer (TNBC) who have failed prior therapies for metastatic disease. The first abstract is a Late-Breaking Abstract on updated results from a Phase 2 study of the ADC in patients with metastatic TNBC. This abstract has also been selected as part of the Best of ASCO Program, which features the top abstracts from this year’s ASCO Annual Meeting for their practice changing research. Results in patients with metastatic non-small-cell lung cancer will be updated in another Clinical Science Symposium Session that focuses on lung cancers. In addition to these two oral presentations, a poster presentation of results with sacituzumab govitecan in patients with metastatic small-cell lung cancer will also be given
http://www.immunomed...
Additional Relevant Details Immunomedics Provides Update on Triple-Negative Breast Cancer Presentation At ASCO
http://www.immunomed...
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 06, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Lung Cancer, Breast Cancer, Sacituzumab Govitecan, Immu-132, Asco